Patent ID: 11911368
Assignee: SUPERNUS PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating ADHD in a mammalian subject comprising:
determining whether a pharmaceutical agent having known activity inhibiting noradrenergic, serotonergic and dopaminergic reuptake transporters also exhibits mu-opioid receptor agonistic activity,
selecting at least one pharmaceutical agent having known activity inhibiting noradrenergic, serotonergic and dopaminergic reuptake transporters which also exhibits mu-opioid receptor agonistic activity,
optimizing total dosage of the at least one pharmaceutical agent having known activity inhibiting noradrenergic, serotonergic and dopaminergic reuptake transporters which also exhibits mu-opioid receptor agonistic activity, and
administering the optimized dose of the at least one pharmaceutical agent to the mammalian subject, wherein the pharmaceutical agent is mazindol as a sole active agent in the administration and wherein the administered dose is an oral daily dose of 0.1-0.5 mg of mazindol.